<DOC>
	<DOCNO>NCT01472081</DOCNO>
	<brief_summary>The purpose determine safety , effectiveness best dose use give Nivolumab combination Sunitinib , Pazopanib , Ipilimumab treatment metastatic renal cell carcinoma .</brief_summary>
	<brief_title>Nivolumab ( BMS-936558 ; MDX-1106 ) Combination With Sunitinib , Pazopanib , Ipilimumab Subjects With Metastatic Renal Cell Carcinoma ( RCC ) ( CheckMate 016 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects histological confirmation RCC Advanced metastatic disease Measurable disease define RECIST 1.1 criterion Karnofsky Performance Status ( KPS ) ≥80 % Available tumor tissue ( archival recent acquisition ) Subjects enrolled I1 , I3 expansion arm IN3 addition arm must receive prior systemic therapy RCC follow exception : 1 . One prior adjuvant neoadjuvant therapy localize locally advanced RCC allow provide recurrence occur ≥ 6 month last dose adjuvant neoadjuvant therapy 2 . Only prior cytokine base treatment metastatic RCC [ eg , interferonalpha ( IFNalpha ) interleukin 2 ( IL2 ) ] prior therapy allow Active central nervous system ( CNS ) metastases Active history autoimmune disease Ongoing symptomatic cardiac dysrhythmias uncontrolled atrial fibrillation History cerebrovascular accident include transient ischemic attack within past 12 month History pulmonary embolism deep vein thrombosis ( DVT ) within past 6 month Chronic systemic steroid ( &gt; 10 mg/day Prednisone equivalent ) immunosuppressive agent White blood cell ( WBC ) &lt; 2,000/mm3 Neutrophiles &lt; 1,500/mm3 Platelets &lt; 100,000/mm3 Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &gt; 3x upper limit normal ( ULN ) Total Bilirubin &gt; 1.5x ULN ( except subject Gilbert syndrome , total bilirubin &lt; 3.0 mg/dL ) Cardiac ejection fraction &lt; LLN ( low limit normal ) Serum creatinine &gt; 1.5x ULN creatinine clearance &lt; 40 mL/min ( CockroftGault formula ) Exclusion Criteria Arm S Arm P : For dose escalation cohort subject receive prior Sunitinib Pazopanib require permanent discontinuation due toxicity require dose reduction delay first 12 week therapy due toxicity , receive prior Sunitinib Pazopanib Poorly control hypertension Active bleeding bleeding susceptibility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>